TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18479284

Group type: COMPARATOR
Intervention: AngioSeal VIP
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: StarClose
Number of subjects: 401
Study: 16787799

Group type: EXPERIMENTAL
Intervention: Boehler's angle (BA)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Critical angle of Gissane (CAG)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Emergency physicians diagnosing without angle measurements
Number of subjects: 133
Study: 14603093

Group type: EXPERIMENTAL
Intervention: Single doses of benzathine penicillin, azithromycin, and cefixime
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Single dose of cefixime and 3 doses of azithromycin given biweekly
Number of subjects: 186
Study: 11164425

Group type: EXPERIMENTAL
Intervention: 400 mg bezafibrate once daily for 6 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control VLDL
Number of subjects: 18
Study: 9342067

Group type: EXPERIMENTAL
Intervention: GM-CSF (300 microg subcutaneously daily for 1 week, then 150 microg subcutaneously two times weekly for 11 weeks)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Non-treated controls
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: GM-CSF (treated group)
Number of subjects: 244
Study: 8210831

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cox model
Number of subjects: 0
Study: 2870732

Group type: EXPERIMENTAL
Intervention: ICI 141,292 200 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ICI 141,292 400 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Atenolol 50 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 13
Study: 30133950

Group type: EXPERIMENTAL
Intervention: HEPA air cleaner
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo 'dummy' air cleaner
Number of subjects: 0
Study: 26569624

Group type: EXPERIMENTAL
Intervention: Melatonin, 3mg/d for 4 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 25721770

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-containing sequential therapy
Number of subjects: 212

Group type: COMPARATOR
Intervention: Clarithromycin-containing sequential therapy
Number of subjects: 212
Study: 23715567

Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapy (n = 122)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo (n = 60)
Number of subjects: 182
Study: 20860413

Group type: EXPERIMENTAL
Intervention: Colesevelam (3.75 g/day)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Colesevelam plus low-dose statin or niacin
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Colesevelam (1.5 g/day to 3.75 g/day)
Number of subjects: 260
Study: 18090355

Group type: EXPERIMENTAL
Intervention: Hemoadsorption using CytoSorb for 4 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study: 15940147

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Beta-methasone-17-valerate (BMV) cream 0.1%
Number of subjects: 22

Group type: COMPARATOR
Intervention: Matching vehicle cream
Number of subjects: 22
Study: 12635579

Group type: EXPERIMENTAL
Intervention: Inhaled heparin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10950768

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 27
Study: 9088806

Group type: EXPERIMENTAL
Intervention: OLITA program (Outpatient Long‐term Intensive Therapy for Alcoholics)
Number of subjects: 30
Study: 1534047

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily in the morning for seven days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily in the evening for seven days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lansoprazole (morning and evening dosing)
Number of subjects: 8
Study: 3996470

Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30736761

Group type: EXPERIMENTAL
Intervention: Non-operative shoulder exercise treatment (not specified dosage or duration)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not receiving non-operative shoulder treatment)
Number of subjects: 56
Study: 28945646

Group type: EXPERIMENTAL
Intervention: Toric contact lenses (TCL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Soft spherical contact lenses (SCL)
Number of subjects: 60
Study: 25241755

Group type: EXPERIMENTAL
Intervention: T-PEMF once daily (active dose in the morning and sham in the afternoon)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: T-PEMF twice daily (active dose both morning and afternoon)
Number of subjects: 65
Study: 23143424

Group type: EXPERIMENTAL
Intervention: Hebrew version of Pelvic Floor Distress Inventory
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Hebrew version of Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Hebrew version of Urgency, Severity and Impact Questionnaire
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Hebrew version of all questionnaires (refilled after 2 weeks)
Number of subjects: 56
Study: 19694925

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 372
Study: 18931219

Group type: EXPERIMENTAL
Intervention: NMBAS-guided rocuronium administration
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 73
Study: 11707843

Group type: EXPERIMENTAL
Intervention: EPOCH chemotherapy (etoposide/doxorubicin/vincristine/cyclophosphamide/prednisone)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: EPOCH chemotherapy
Number of subjects: 93
Study: 9203934

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily for four weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7692755

Group type: EXPERIMENTAL
Intervention: Therapy for recurrent malignant neoplasia (pure yolk sac tumor or teratoma with yolk sac elements)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Microscopic examination of original tumors
Number of subjects: 6
Study: 3114808

Group type: EXPERIMENTAL
Intervention: 4 mg alprazolam PO daily as 2 mg bid
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1 mg qid
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.25 mg each hour
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29766330

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment alone (Er group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined treatment with Nd:YAG and Er:YAG lasers (NdErNd group)
Number of subjects: 60
Study: 28162931

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Staged multicomponent tailored behavioral interventions (e.g., electronic monitoring feedback, motivational interviewing)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control Group (CG) - Usual care
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 205
Study: 26241254

Group type: EXPERIMENTAL
Intervention: Oral midazolam 10 mg administered 30-60 minutes before surgical abortion.
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo administered 30-60 minutes before surgical abortion.
Number of subjects: 124
Study: 23882930

Group type: EXPERIMENTAL
Intervention: Valganciclovir for 200 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Valganciclovir for 110 days
Number of subjects: 100
Study: 20803856

Group type: EXPERIMENTAL
Intervention: 5 ml*h(‐1) ropivacaine 0.2% (study group, n = 21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 5 ml*h(‐1) saline (control group, n = 21)
Number of subjects: 42
Study: 18763292

Group type: EXPERIMENTAL
Intervention: Personal stage nutrition support
Number of subjects: 43

Group type: COMPARATOR
Intervention: Total parental nutrition (TPN) in combination with operation
Number of subjects: 43
Study: 16377319

Group type: EXPERIMENTAL
Intervention: Cytolong brush (CB)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Geenen brush (GB)
Number of subjects: 102
Study: 12571499

Group type: EXPERIMENTAL
Intervention: Subtalar distraction bone‐block arthrodesis with tricortical bone graft
Number of subjects: 424

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 424

Group type: COMPARATOR
Intervention: Open reduction and internal fixation
Number of subjects: 424

Group type: COMPARATOR
Intervention: Böhler angle <0 degrees
Number of subjects: 424

Group type: COMPARATOR
Intervention: Sanders-type IV fractures
Number of subjects: 424

Group type: COMPARATOR
Intervention: Worker's Compensation Board status
Number of subjects: 424
Study: 11086664

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: granisetron 2 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 8828422

Group type: EXPERIMENTAL
Intervention: Continuous hormone replacement therapy (first 6 months)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Suspension of hormone replacement therapy (first 6 months)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Resumption of hormone replacement therapy (after 6 months)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Suspension of hormone replacement therapy (after 6 months)
Number of subjects: 23
Study: 1448310

Group type: EXPERIMENTAL
Intervention: Miconazole oral gel
Number of subjects: 757

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 757
Study: 30689736

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy (nivolumab)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Major pathologic response on biopsy (MPRbx)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Stable disease
Number of subjects: 51
Study: 28926525

Group type: EXPERIMENTAL
Intervention: Be Resilient to Breast Cancer (BRBC)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 226
Study: 26960919

Group type: EXPERIMENTAL
Intervention: Successful extubation
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Extubation failure
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Extubation failure (adjusted for allocated treatment)
Number of subjects: 174
Study: 25359435

Group type: EXPERIMENTAL
Intervention: SleepPro 1™ (SP1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SleepPro 2™ (SP2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bespoke MAD (bMAD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 90
Study: 22735801

Group type: EXPERIMENTAL
Intervention: Intravitreal Triamcinolone Acetonide (4 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intravitreal Bevacizumab (1.25 mg)
Number of subjects: 55
Study: 19534840

Group type: EXPERIMENTAL
Intervention: Cochrane Database of Systematic Reviews (CDSR)
Number of subjects: 0
Study: 18510694

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16430011

Group type: EXPERIMENTAL
Intervention: Total-etch adhesive (Adper Scotchbond MultiPurpose) with incremental insertion technique
Number of subjects: 48

Group type: COMPARATOR
Intervention: Self-etching adhesive (iBond) with bulk insertion technique
Number of subjects: 48
Study: 12614089

Group type: EXPERIMENTAL
Intervention: Providing physicians with alcohol screening results and recommendations for their patients at a visit.
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Patients who saw resident physicians in the intervention group.
Number of subjects: 312
Study: 10583283

Group type: EXPERIMENTAL
Intervention: Double gloving
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single gloving
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Deep surgical procedures
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Superficial surgical procedures
Number of subjects: 80
Study: 8904621

Group type: EXPERIMENTAL
Intervention: 40 mg daily simvastatin
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: 20 mg daily simvastatin
Number of subjects: 621

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 621
Study: 1809526

Group type: EXPERIMENTAL
Intervention: Pyrimethamine prophylaxis
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 6400110

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30507677

Group type: EXPERIMENTAL
Intervention: SstO2 monitoring during surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: SstO2 monitoring
Number of subjects: 50
Study: 28622463

Group type: EXPERIMENTAL
Intervention: Filgotinib (100 mg twice daily or 30, 75, 150, 200, or 300 mg once daily)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 26565785

Group type: EXPERIMENTAL
Intervention: RLO+ (interactive videos plus standard clinical service)
Number of subjects: 203

Group type: COMPARATOR
Intervention: RLO- (standard clinical service only)
Number of subjects: 203
Study: 25121980

Group type: EXPERIMENTAL
Intervention: Parotid gland massage for 1 minute
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Parotid gland massage for 2 minutes
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (1-minute interval without massage)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (2-minute interval without massage)
Number of subjects: 44
Study: 21875223

Group type: EXPERIMENTAL
Intervention: Nicotine (6 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 20
Study: 19786825

Group type: EXPERIMENTAL
Intervention: Acetylcholine iontophoresis at the upper site on the forearm
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acetylcholine iontophoresis at the lower site on the forearm
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Repeated iontophoresis at the same site
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Data expressed as percentage of shared variance after heating
Number of subjects: 16
Study: 17532416

Group type: EXPERIMENTAL
Intervention: C‐E Perimount (stented bioprosthesis)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Prima Plus (stentless bioprosthesis)
Number of subjects: 161
Study: 15189262

Group type: EXPERIMENTAL
Intervention: Problem-oriented practical (POP) course
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Personal bedside teaching (PBT) course
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard practical course
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: POP and PBT courses
Number of subjects: 228
Study: 11172123

Group type: EXPERIMENTAL
Intervention: Laparoscopic Burch colposuspension
Number of subjects: 74

Group type: COMPARATOR
Intervention: Classic Burch colposuspension
Number of subjects: 74
Study: 10338904

Group type: EXPERIMENTAL
Intervention: Salmeterol aerosol 42 micrograms twice daily
Number of subjects: 538

Group type: COMPARATOR
Intervention: Placebo (as‐needed albuterol)
Number of subjects: 538
Study: 8275438

Group type: EXPERIMENTAL
Intervention: 500 mg gabexate mesilate, intravenously twice a day for 5 days after TAE
Number of subjects: 34

Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 500 mg gabexate mesilate
Number of subjects: 34
Study: 2498383

Group type: COMPARATOR
Intervention: 4-hour continuous intravenous infusion of GH (180-micrograms bolus dose, then 3 micrograms/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 6-hour continuous intravenous infusion of GH (180-micrograms bolus dose, then 3 micrograms/min)
Number of subjects: 8
Study: 30664549

Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde (TRPA1 sensitizer)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Capsaicin (TRPV1 sensitizer)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Menthol (TRPM8 sensitizer)
Number of subjects: 16
Study: 29121724

Group type: EXPERIMENTAL
Intervention: Apixaban (n=104)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Dabigatran (n=160)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (n=150)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Higher CHA2DS2-VASc score
Number of subjects: 414
Study: 26502785

Group type: EXPERIMENTAL
Intervention: Telephone intervention program (1-year systematic follow-up)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 0
Study: 23246672

Group type: EXPERIMENTAL
Intervention: 30% O2
Number of subjects: 13

Group type: COMPARATOR
Intervention: Compressed Air (CA)
Number of subjects: 13
Study: 21592510

Group type: EXPERIMENTAL
Intervention: Minimal resuscitation (n = 343)
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Bag-mask ventilation (n = 372)
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (n = 1205)
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation (n = 86)
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: All levels of resuscitation
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Adjusted rates of bronchopulmonary dysplasia and severe retinopathy
Number of subjects: 2006
Study: 17852721

Group type: EXPERIMENTAL
Intervention: Thought suppression paradigm with autobiographical experiences as target thoughts
Number of subjects: 0
Study: 17067136

Group type: EXPERIMENTAL
Intervention: Magnesium 40 mg x kg(‐1) for 5 min at 6.5 min before induction
Number of subjects: 55

Group type: COMPARATOR
Intervention: Vecuronium 0.02 mg x kg(‐1) at 1.5 min before induction
Number of subjects: 55

Group type: COMPARATOR
Intervention: Saline 1-2 ml at 1.5 min before induction
Number of subjects: 55
Study: 12667899

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (10%, 30%, and 50% N(2)O in O(2))
Number of subjects: 13

Group type: COMPARATOR
Intervention: 100% O(2) (placebo)
Number of subjects: 13
Study: 9862836

Group type: EXPERIMENTAL
Intervention: Transabdominal bowel sonography (T)
Number of subjects: 213
Study: 8551420

Group type: EXPERIMENTAL
Intervention: Reduced osmolarity ORS (245 mmol/L sodium and glucose)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard WHO ORS (311 mmol/L)
Number of subjects: 190
Study: 1880751

Group type: EXPERIMENTAL
Intervention: Coded consonants at F=500 Hz
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coded consonants at F=300 Hz
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lowpass filtered speech at F=500 Hz
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lowpass filtered speech at F=300 Hz
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coded vowels at F=500 Hz
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coded vowels at F=300 Hz
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coded consonants in CV syllables at F=500 Hz
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coded vowels in CV syllables at F=500 Hz
Number of subjects: 24
Study: 6882881

Group type: EXPERIMENTAL
Intervention: Effervescent acetylsalicylic acid (ASA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Experimental ASA formulation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Unbuffered ASA
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Effervescent ASA
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Experimental ASA
Number of subjects: 8
Study: 30132262

Group type: EXPERIMENTAL
Intervention: Metformin (850-1700 mg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 29980120

Group type: EXPERIMENTAL
Intervention: Building Spiritual Strength (BSS)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Present Centered Group Therapy (PCGT)
Number of subjects: 138
Study: 28471773

Group type: EXPERIMENTAL
Intervention: Atropine premedication
Number of subjects: 41

Group type: COMPARATOR
Intervention: No atropine premedication
Number of subjects: 41
Study: 26595894

Group type: EXPERIMENTAL
Intervention: Individually oriented monetary reward incentives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Purely altruistic monetary reward incentives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hybrid of competitive and cooperative monetary reward incentives
Number of subjects: 0

Group type: COMPARATOR
Intervention: No incentive control condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All incentives (individually oriented, altruistic, competitive/cooperative)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Independent cognitive testing battery
Number of subjects: 0
Study: 23320440

Group type: EXPERIMENTAL
Intervention: Cross-examination-style questioning
Number of subjects: 185

Group type: COMPARATOR
Intervention: Direct examination questions
Number of subjects: 185
Study: 21603629

Group type: EXPERIMENTAL
Intervention: Artesunate 2 mg/kg/day
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Artesunate 4 mg/kg/day
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Artesunate 6 mg/kg/day
Number of subjects: 143
Study: 19000552

Group type: EXPERIMENTAL
Intervention: Single dose of 25 mg pactimibe
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Multiple doses of 100 mg pactimibe for 21 days in CYP2D6 PMs
Number of subjects: 24
Study: 16797395

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12717144

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 45